Standard Operating Procedure for Out-of-Specification (OOS) Handling in API Manufacturing
Department | API Manufacturing |
---|---|
SOP No. | SOP/API/134/2025 |
Supersedes | SOP/API/134/2022 |
Page No. | Page 1 of 9 |
Issue Date | 13/04/2025 |
Effective Date | 15/04/2025 |
Review Date | 13/04/2026 |
1. Purpose
To establish a systematic procedure for handling Out-of-Specification (OOS) results generated during testing of raw materials, intermediates, and final Active Pharmaceutical Ingredients (APIs), ensuring thorough investigation, documentation, and compliance with applicable regulations.
2. Scope
This SOP applies to all Quality Control (QC) personnel, analysts, reviewers, and QA officers involved in handling and investigating test results that fall outside approved specification limits
3. Responsibilities
- QC Analyst: Identify and report OOS results immediately and initiate documentation.
- QC Reviewer: Confirm the validity of the result and initiate investigation if required.
- QA Officer: Participate in investigation, approve corrective/preventive actions, and close the OOS record.
- Department Head (QC/QA): Review the investigation, assess impact, and approve final disposition.
4. Accountability
The Head – Quality Assurance is accountable for ensuring timely and compliant investigation and resolution of all OOS events in accordance with regulatory expectations and internal SOPs.
5. Procedure
5.1 Identification of OOS
- An OOS result is defined as any test result that falls outside the approved specification or acceptance criteria.
- OOS results may arise during testing of:
- Raw materials
- In-process materials
- Finished APIs
- Stability samples
- Analyst must immediately inform the QC supervisor and record the result in the OOS Notification Form (Annexure-1).
5.2 Phase I: Laboratory Investigation
- Review the analytical method, calculation, raw data, instrument logs, reagents, and analyst’s technique.
- Perform a system suitability check.
- If no obvious errors are found, repeat the test using the same sample preparation (if stable).
- If the repeat result is within limits and there is an assignable error, document and conclude.
- If the repeat result is still OOS or the cause is not found, proceed to Phase II.
5.3 Phase II: Full-Scale Investigation
- QA initiates a formal investigation using OOS Investigation Form (Annexure-2).
- Investigate:
- Manufacturing process deviations
- Sample mix-up or contamination
- Storage conditions
- Previous batch trends and history
- Interview involved personnel and document findings.
- Define root cause and propose CAPA (Corrective and Preventive Action).
- QA reviews and approves the investigation report.
5.4 Re-sampling and Re-testing Criteria
- Re-sampling is allowed only if there is evidence of sample compromise or handling error.
- Re-testing is permitted under QA-approved protocol with documented justification.
- Original OOS result cannot be disregarded unless invalidated with scientifically sound reason.
5.5 Final Disposition
- Based on investigation outcome, QA recommends:
- Batch rejection
- Reprocessing or re-testing
- Product recall or reporting to regulatory authorities (if applicable)
- Final decision is documented in the OOS Final Disposition Log (Annexure-3).
5.6 Trending and Review
- QA shall review all closed OOS records quarterly to identify recurring issues.
- Prepare trend reports and present during management review meetings.
6. Abbreviations
- OOS: Out of Specification
- CAPA: Corrective and Preventive Action
- QA: Quality Assurance
- QC: Quality Control
- SOP: Standard Operating Procedure
7. Documents
- OOS Notification Form (Annexure-1)
- OOS Investigation Form (Annexure-2)
- OOS Final Disposition Log (Annexure-3)
- CAPA Register
8. References
- US FDA Guidance for Industry: Investigating Out-of-Specification (OOS) Test Results
- ICH Q7 – GMP for APIs
- 21 CFR Part 211
- MHRA GxP Data Integrity Guidance
9. SOP Version
Version: 2.0
10. Approval Section
Prepared By | Checked By | Approved By | |
---|---|---|---|
Signature | |||
Date | |||
Name | |||
Designation | |||
Department |
11. Annexures
Annexure-1: OOS Notification Form
Date | Sample ID | Test | Result | Limit | Analyst | Supervisor Signature |
---|---|---|---|---|---|---|
13/04/2025 | API-20250413 | Assay | 91.2% | 95–105% | Sunita Reddy | Rajesh Kumar |
Annexure-2: OOS Investigation Form
Investigation No. | OOS/025/2025 |
---|---|
Details of Deviation | Assay below limit |
Root Cause | Weighing error during sample prep |
CAPA Proposed | Retraining of analysts, balance calibration check |
QA Review Comments | Adequate and accepted |
Annexure-3: OOS Final Disposition Log
Date | Sample ID | Result | Disposition | QA Sign |
---|---|---|---|---|
15/04/2025 | API-20250413 | OOS Confirmed | Batch Rejected | QA Head |
Revision History:
Revision Date | Revision No. | Details | Reason | Approved By |
---|---|---|---|---|
01/01/2022 | 1.0 | Initial SOP | Regulatory Compliance | QA Head |
13/04/2025 | 2.0 | Added trending and disposition log | Internal Audit Observation | QA Head |